Treatment of muscle fatigue

• US 20060078596A1
• Filed: 11/28/2005
• Published: 04/13/2006
• Est. Priority Date: 06/02/2003
• Status: Active Application

• Current Assignee: Oxford University Innovation Limited (University of Oxford)
• Original Assignee: Oxford University Innovation Limited (University of Oxford)
• Inventors: Clarke, Kieran, Scheuermann-Freestone, Michaela, Murray, Andrew James
• Application Number:
  US11/287,803
• Publication Number:
  US 20060078596A1
• Time in Patent Office: Days
• US Class Current: 424/439
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/216 of acids having aromatic rings, e.g. benactizyne, clofibrate
• CPC Class Codes: A61K 31/455 Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention involves the use of a compound that reduces the level of free fatty acids circulating in the plasma of a subject in the manufacture of a medicament for the treatment of prevention of muscle (particularly cardiac or skeletal muscle) impairment or fatigue.

Claims

1. A method for preventing and treating muscle fatigue comprising the step of administering to a subject a compound that reduces concentrations of free fatty acids circulating in the plasma of the subject, wherein the muscle is selected from the group consisting of cardiac and skeletal muscle.

2. The method according to claim 1 wherein the concentrations of free fatty acids in the plasma of the subject is due to a disorder associated with mitochondrial dysfunction.

3. The method according to claim 1 wherein the concentrations of free fatty acids in the plasma of the subject is due to impairment of muscle function.

4. The method according to claim 1 wherein the subject has diabetes.

5. The method according to claim 4 wherein the diabetes is type 2 diabetes.

6. The method according to claim 1 wherein the compound is selected from the group consisting of ketone bodies, nicotinic acid, salicyclic acid, thiazolidine diones, and fibrates.

7. The method according to claim 1 wherein the compound is in the form selected from the group consisting a food supplement and a liquid composition.

13. The method according to claim 1, wherein the subject is healthy and non-obese.

8. A composition for rehydrating a subject, the composition comprising water, a sugar carbohydrate, and a compound that reduces concentrations of free fatty acids circulating in the plasma of the subject, wherein rehydrating the subject is preformed at a period selected from the group consisting of during an exercise period and following an exercise period.

9. The composition according to claim 8 wherein the sugar carbohydrate is glucose.

10. A method for monitoring cardiac muscle function in a subject, the method comprising the steps of:

i) measuring concentrations of free fatty acids in a blood plasma sample from a fasted subject and ii) quantifying the result with levels of free fatty acids sampled from a control subject.

11. The method according to claim 10, wherein cardiac muscle function shows impairment at a concentration of free fatty acids of greater that 0.5 mM in a blood plasma sample from a subject undertaking a diet.

12. The method according to claim 11, wherein the subject is undertaking a high-fat low-carbohydrate diet.

14. A device for monitoring cardiac muscle function, the device comprising means for measuring the concentrations of free fatty acids in a plasma sample.

15. The device according to claim 14, wherein the device is a hand-held device and is shaped, sized, and adapted for use in the hand of an individual.

16. The device according to claim 14, wherein the device further comprises an electrochemical cell.